

Index

- abdominal striae, gravid patient, 424
 abdominal wall defects, 183, 185
 abdominal wall laxity, 291–92
 abnormal fetal growth
 factors, classifications, 161–62
 fetal growth restrictions, fetal risk factors, 163
 fetal growth restrictions, maternal risk factors, 163
 fetal growth restrictions, placental risk factors, 163–64
 fetal growth restrictions management, Growth Intervention Restriction Trial (GRIT), 164–66
 fetal macrosomia, diagnosis, 166
 fetal macrosomia, management, 166
 fetal macrosomia, risk factors, 166
 prenatal diagnosis, 162–63
 scope of problem, 162
 symmetric vs. asymmetric IUGR, 164
 abnormal labor. *See* labor, abnormal
 achalasia, 377–78
 ACOG. *See* American Congress of Obstetrics and Gynecology
 acromegaly, 393
 acute, chronic respiratory health assessment, 332
 acute chest syndrome (ACS), 337–38
 acute fatty liver pregnancy (AFLP), 359, 381
 acute kidney injury (AKI), 356, 359
 diagnosis, 359
 general management, 359
 acute onset neurological signs, symptoms, 345f. 38.1
 acute stroke, differential diagnosis, 346
 addiction neurobiology, 465
 addiction stages, 466
 adrenal insufficiency, 394
 Albucasis of Cordova, 498
 alcohol abuse
 background/epidemiology, 466–67
 diagnosis, 467
 screening, 467
 treatment, 467
 alloimmunization, non-immune hydrops fetalis (NIHF)
 ABO incompatibility, 176
 alloimmune
 thrombocytopenia, 176–77
 alloimmunization, 173–74
 alloimmunization,
 pathophysiology, 174–75
 anti-D sensitized pregnancies, fetal assessment and treatment, 175
 cardiac anomalies, 170–72
 delivery route, 173
 diagnosis, 170
 fetal anemia, 172
 immunoglobulin dosage calculation, 176
 management, 172–73
 mirror syndrome, Ballantyne's syndrome, 173
 non-rhesus-D antigens, atypical antibodies, 176
 other anomalies, 172
 pathogenesis, diagnosis, 169–70
 possible future management changes, 177
 scope of problem, 169
 sensitized pregnancies, initial care, 175
 severe anemia secondary to alloimmunization, neonate care, 175–76
 signs, examples, 169
 ambiguous genitalia, 183
 American Congress of Obstetrics and Gynecology (ACOG), 8
 analgesia, anesthesia
 analgesia for labor, 105–10
 block height assessment, 111
 cesarean general anesthesia, accidental awareness (AAGA), 114
 cesarean general anesthesia, conduct of general anesthesia, 113
 cesarean general anesthesia, failed intubation, 113–14
 cesarean general anesthesia, gastric contents aspiration, 112
 cesarean general anesthesia, maternal airway, 112
 cesarean regional anesthesia, blood loss, 110
 cesarean regional anesthesia, combined spinal-epidural anesthesia (CSE), 111
 cesarean regional anesthesia, contraindications, 110
 cesarean regional anesthesia, epidural anesthesia, 111
 cesarean regional anesthesia, intra-operative care, 112
 cesarean regional anesthesia, postoperative analgesia, 112
 cesarean regional anesthesia, postoperative analgesia and recovery, 110
 cesarean regional anesthesia, preoperative preparation, 110
 cesarean regional anesthesia, safety, 110
 cesarean regional anesthesia, spinal anesthesia, 111
 cesarean regional anesthesia fluid, blood pressure management, 111
 epidural analgesia, initiation, 108
 epidural insertion, 107–08
 general anesthesia risks, 106
 inhalational analgesia, Etonox, 105–06
 labor pain physiology, first stage of labor, 106–07
 labor pain physiology, second stage of labor, 107
 non-pharmacological analgesia in labor, 105
 opioids, meperidine, 106
 opioids, patient-controlled analgesia (PCA), 106
 other techniques in labor, 105
 patient consent, in labor, 107
 pharmacological analgesia in labor, 105–06
 regional analgesia, 106
 regional analgesia side effects, accidental intravenous injection, 109–10
 regional analgesia side effects, hypotension, 109
 regional analgesia side effects, neurological damage, 110

Index

- analgesia, anesthesia (*Cont.*)
 regional analgesia side effects,
 obstetric outcomes effect, 110
 regional analgesia side effects, total
 spinal, 109
 regional analgesia side effects,
 unilateral or partial blockade, 109
 regional analgesia/anesthesia
 risks, 106
 regional anesthesia,
 contraindications, 108
 regional anesthesia, indications, 107
 regional anesthesia, special
 circumstances, 108
 scope of problem, 105
 transcutaneous electrical nerve
 stimulation (TENS), 105
*The Anatomy of the Human Gravid
 Uterus* (Hunter), 500
 anemia, 367–68
 antepartum hemorrhage, special
 antenatal considerations
 premature birth outcomes
 optimization, 249
 RdD alloimmunization prevention, 249
 antepartum hemorrhage. *See also* post-
 partum hemorrhage
 etiology, 245
 placenta abruption, defined, 247
 placenta abruption,
 diagnosis, 247–48
 placenta abruption, outcomes, 248
 placenta abruption, risk factors, 247
 placenta accreta, diagnosis, 247
 placenta accreta, outcomes, 246, 247
 placenta accreta, risk factors, 246
 placenta previa, classification, 246
 placenta previa, defined, 245
 placenta previa, diagnosis, 245–46
 placenta previa, outcomes, 246
 placenta previa, risk factors, 245
 scope of problem, 245
 secondary causes, 246
 vasa previa, antepartum
 diagnosis management
 recommendations, 249
 vasa previa, antepartum
 screening, 249
 vasa previa, definition, 248
 vasa previa, outcomes, 249
 vasa previa, risk factors, 248–49
 antiphospholipid Syndrome
 (APS), 362–63
 antipsychotics, 462
 appendicitis, 383
 asthma symptoms, 336
 asymptomatic bacteriuria, acute
 cystitis, pyelonephritis, 360–61
 atopic eruptions, 428–29
 autonomic hyperreflexia, 493
 autosomal dominant polycystic
 kidney disease (ADPKD), 363–64
 Avicena of Bokhara, 498
 baby blues, 454
 risk factors, 455
 treatment, 455
 baseline pulmonary parameters, 333
 Bell's palsy (BP), 353
 bicuspid aortic valve and aortic
 stenosis, 328
 bioprosthetic, mechanical heart
 valves, 329–30
 bipolar disorder, 457
 pharmacological treatment, 458
 risk factors, 457–58
 treatment, 458
 Bourgeois, Louyse, 501
 bowel dysfunction, 74
 breast cancer
 diagnosis, 479–80
 early stage stage I and II, 480
 epidemiology, 479
 lactation, 480
 late stage stage III and IV, 480
 bronchiectasis, 338
 calcium metabolism, parathyroid
 disease, 390
 cancer
 breast cancer, diagnosis, 479–80
 breast cancer, early stage stage I
 and II, 480
 breast cancer, epidemiology, 479
 breast cancer, lactation, 480
 breast cancer, late stage stage III
 and IV, 480
 cervical cancer, diagnosis, 480–81
 cervical cancer, epidemiology, 480
 cervical cancer, treatment, 481
 hematologic malignancies,
 epidemiology, 482
 hematologic malignancies, lymphoma
 treatment, 482
 hematologic malignancies,
 treatment, 482
 ovarian cancer, diagnosis, 482
 ovarian cancer,
 epidemiology, 481–82
 scope of problem, 479
 cardiac abnormalities, 182
 cardiac abnormality risk, by maternal
 lesion, 326
 cardiovascular disease
 bioprosthetic, mechanical heart
 valves, 329–30
 cardiac abnormality risk, by
 maternal lesion, 326
 CARPREG risk score, 326–27
 congenital heart disease, 327
 congenital heart disease, cyanotic
 heart conditions, 327–28
 congenital heart disease,
 intracardiac communications, 327
 congenital heart disease, pulmonary
 hypertensions, Eisenmenger's
 syndrome, 327
 evaluation of heart during
 pregnancy, 325
 great vessels transposition, impaired
 systemic right ventricle, 328
 hemodynamic adaptations to
 pregnancy, 325
 inherited lesions, bicuspid aortic
 valve and aortic stenosis, 328
 inherited lesions, Marfan
 syndrome, 328
 maternal mortality associated with
 pregnancy, 326t. 36.2
 maternal physiology, 325t. 36.1
 myocardial infarction (MI), 328
 New York Heart Association
 classification, 326
 normal pregnancy vs. heart failure,
 325t. 36.1
 peripartum cardiomyopathy
 (PPCM), 329
 preconception counseling, 325–26
 scope of problem, 324
 Tetralogy of Fallot (TOF), 328
 CARPREG risk score, 326–27
 cerebrovascular disease, 344
 cerebrovascular events in pregnancy,
 preexisting factors, 346
 cervical cancer
 diagnosis, 480–81
 epidemiology, 480
 treatment, 481
 cesarean delivery complications
 birth experience, psychological
 outcome, 74
 bowel dysfunction, 74
 cesarean hysterectomy (CH), 66–68,
 74–75
 emergency hysterectomy, 73–74
 hemorrhage, 73
 infection, 73
 maternal death, 72
 pain, 74
 scope of problem, 72
 septic pelvic thrombophlebitis, 74
 surgical injuries, 73
 thromboembolism, 72–73
 cesarean delivery complications, fetal
 and neonatal risks
 asthma, 76
 breastfeed failure, 76

- respiratory difficulties, transient
 tachypnea of newborn
 (TNN), 75–76
- trauma, 76
- cesarean delivery complications,
 long-term risks
- abnormal placentation, 76
- adhesion formation, 76
- hospital readmission, 76
- infertility/subfertility, 76
- long-term pain, 76
- stillbirth, 76
- uterine rupture, 77
- uterine scar complications, 76–77
- cesarean general anesthesia
- accidental awareness (AAGA), 114
- conduct of general anesthesia, 113
- failed intubation, 113–14
- gastric contents aspiration, 112
- maternal airway, 112
- cesarean regional anesthesia
- blood loss, 110
- combined spinal-epidural anesthesia
 (CSE), 111
- contraindications, 110
- epidural anesthesia, 111
- fluid, blood pressure
 management, 111
- intra-operative care, 112
- postoperative analgesia, 112
- postoperative analgesia and
 recovery, 110
- preoperative preparation, 110
- safety, 110
- spinal anesthesia, 111
- cesarean section (CS)
- cesarean hysterectomy (CH), 66–68,
 74–75
- elective, 64–65
- history, 64
- post-operative management, 68
- post-operative morbidity, 68
- statement of problem, 64
- surgical preparation, precautions, 65–66
- surgical technique, 66–68
- cesarean section (CS), vaginal
- birth after
- prenatal patient care, 83
- risks, benefits,
 decision-making, 80–83
- scope of problem, 80
- trial of labor after cesarean
 (TOLAC), 80–83
- trial of labor management, 83–84
- uterine rupture during labor, 84
- Chamberlen forceps, 505
- chest, abdominal pain, 291–92
- chickenpox, 334–35
- cholecystitis, 382
- choleithiasis, 382
- chorioamnionitis. *See* intraamniotic
 infection, chorioamnionitis
- differential diagnosis, 198–99
- chorioangioma, 37
- complications, 39
- management, 39
- chromosomal abnormalities, 179–80
- chronic glomerulonephritis, 363
- chronic hypertension, 361
- chronic kidney disease antepartum
- evaluation, fetal surveillance,
 postpartum care, 361
- chronic renal diseases, 355
- circumvallate placenta, 37
- complications, 38
- management, 38
- cirrhosis, 381
- coagulation factors, effect of pregnancy
 on, 367
- Coan Prognosis*, 508
- colon disorders, 383–84
- colon during pregnancy, 376
- congenital adrenal hyperplasia
 (CAH), 395–96
- congenital heart disease
- cyanotic heart conditions, 327–28
- intracardiac communications, 327
- pulmonary hypertensions,
 Eisenmenger’s syndrome, 327
- conjoined twins, 207
- connective tissue disorders, hereditary
- Ehlers Danlos syndrome (EDS), 419
- Ehlers Danlos syndrome (EDS),
 antepartum management, 419–20
- Ehlers Danlos syndrome (EDS),
 labs, 419
- Ehlers Danlos syndrome (EDS),
 postpartum considerations, 420
- Ehlers Danlos syndrome (EDS),
 preconception, 419
- Ehlers Danlos syndrome (EDS),
 treatment and medications, 420
- Marfan syndrome, 418–19
- Marfan syndrome, antepartum
 management, 419
- Marfan syndrome, postpartum
 considerations, 419
- Marfan syndrome,
 preconception, 419
- Marfan syndrome, treatment and
 medications, 419
- osteogenesis imperfecta (OI), 420
- osteogenesis imperfecta (OI),
 antepartum management, 421
- osteogenesis imperfecta (OI),
 labs, 420
- osteogenesis imperfecta (OI),
 postpartum considerations, 421
- osteogenesis imperfecta (OI),
 preconception, 420
- osteogenesis imperfecta (OI),
 treatment and medications, 421
- connective tissue disorders, immune
 mediated
- polymyositis, dermatomyositis, 418
- rheumatoid arthritis (RA), 415
- rheumatoid arthritis (RA),
 antepartum management, 416
- rheumatoid arthritis (RA),
 labs, 416
- rheumatoid arthritis
 (RA), postpartum
 considerations, 416–17
- rheumatoid arthritis (RA),
 preconception, 415–16
- rheumatoid arthritis (RA),
 treatment and medications, 416
- scleroderma, 417
- scleroderma, antepartum
 management, 417–18
- scleroderma, labs, 417
- scleroderma, postpartum
 considerations, 418
- scleroderma, preconception, 417
- scleroderma, treatment and
 medications, 418
- Sjögren’s syndrome, 414
- Sjögren’s syndrome, antepartum
 management, 415
- Sjögren’s syndrome, labs, 415
- Sjögren’s syndrome, postpartum
 considerations, 415
- Sjögren’s syndrome,
 preconception, 414–15
- Sjögren’s syndrome, treatment and
 medication, 415
- systemic lupus erythematosus
 (SLE), 412
- systemic lupus erythematosus (SLE),
 antepartum management, 412–13
- systemic lupus erythematosus (SLE),
 labs, 412
- systemic lupus erythematosus
 (SLE), postpartum
 considerations, 413–14
- systemic lupus erythematosus
 (SLE), preclampsia vs. lupus
 nephritis, 413
- systemic lupus erythematosus (SLE),
 preconception, 412
- systemic lupus erythematosus (SLE),
 treatment and medications, 413
- undifferentiated, mixed connective
 tissue disease, overlap
 syndrome, 418
- Consortium on Safe Labor, 8
- constipation, 383–84

Index

- cranioclast illustration, crushed fetal head, 506f. 53.9
 Crohn's Disease (CD), 383
 Cushing's syndrome, 395
 cyanotic heart conditions, 327–28
 cystic fibrosis (CF) and, 335
 cytomegalovirus (CMV), 433–34
- da Vinci, Leonardo, 499
De Contagione et Contagiosis Morbis (Fracastoro), 507
De humani corporis fabrica (Vesalius), 499
 debubitus ulcers, 493
 dermatologic disorders
 abdominal striae, gravid patient, 424
 atopic eruptions, 428–29
 eczema, 429
 intrahepatic cholestasis, 427–28
 normal skin changes, 424
 pemphigoid gestationis, 426–27
 polymorphic eruption, pruritic urticarial papules and plaques of pregnancy (PUPPP), 425–26
 prurigo, 429
 pruritic folliculitis, 429
 scope of problem, 424
 summary of disorders table, 430t. 45.1
 desmoid tumors, fibromatosis, 292
 diabetes insipidus (DI), 393
 diabetes mellitus
 classification, 399
 diagnosis, gestational, 400–01
 diagnosis, pregestational, 399–400
 gestational, 399
 scope of problem, 399
 Type 1, 399
 Type 2, 399
 diabetes mellitus, complications in pregnancy (fetal, neonatal)
 congenital malformations, 403
 hypoglycemia, 403–04
 macrosomia, 403
 other neonatal complications, 404
 respiratory distress syndrome (RDS), 403
 diabetes mellitus, complications in pregnancy (maternal)
 diabetic ketoacidosis (DKA), 402–03
 hypertension, 401
 miscarriage, 403
 nephropathy, 401–02
 retinopathy, 401
 diabetes mellitus, management strategies
 blood glucose control, 404
 diet and exercise, 404
 diet and exercise, all pregnant patients with diabetes, 405
 diet and exercise, gestational diabetes, 404–05
 fetal assessment, diabetic patients, 407
 fetal wellbeing, 406
 gestational diabetes, management, 407
 gestational diabetes, postpartum care, 407
 glyburide, 405
 goals, initial diagnosis, 404
 insulin therapy, 406
 metformin, 405
 other oral hypoglycemic agents, 405–06
 timing, delivery mode, 406–07
 diabetic nephropathy, 362
 dialysis dependent chronic renal failure, 363
 disability in pregnancy
 multiple sclerosis (MS), 495–96
 rheumatoid arthritis (RA), 494–95
 rheumatoid arthritis (RA), breastfeeding, 495
 rheumatoid arthritis (RA), classification criteria, 495
 rheumatoid arthritis (RA), contraception, 495
 scope of problem, 491–92
 spinal cord injury (SCI), 492–93
 spinal cord injury (SCI), autonomic hyperreflexia, 493
 spinal cord injury (SCI), contraception, 494
 spinal cord injury (SCI), debubitus ulcers, 493
 spinal cord injury (SCI), labor and delivery issues, 493–94
 spinal cord injury (SCI), sexual issues, 494
 spinal cord injury (SCI), urinary tract infections, 494
 disseminated intravascular coagulation, 373–74
- eczema, 429
 Ehlers Danlos syndrome (EDS)
 antepartum management, 419–20
 labs, 419
 postpartum considerations, 420
 preconception, 419
 treatment and medications, 420
 Eisenmenger's syndrome, 327
 electroconvulsive therapy (ECT), 462
 emergency hysterectomy, 73–74
 endocrine disorders
 acromegaly, 393
 adrenal insufficiency, 394
 calcium metabolism, parathyroid disease, 390
 congenital adrenal hyperplasia (CAH), 395–96
 Cushing's syndrome, 395
 diabetes insipidus (DI), 393
 hyperparathyroidism, 390–91
 hyperthyroidism, 388–89
 hypoparathyroidism, 391
 hypopituitarism causes, 392
 hypothyroidism, 387–88
 lipid disorders, 396
 lymphocytic hypophysitis, 392
 osteoporosis, 391–92
 pheochromocytoma, 394–95
 pituitary insufficiency, 392
 post-partum thyroiditis (PPT), 389–90
 primary hyperaldosteronism, 395
 prolactinomas, 392–93
 scope of problem, 387
 Sheehan syndrome, 392
 specific hormones, effects of pregnancy on, 396
 thyroid disease, 387
 thyroid nodules, 390
 Vitamin D deficiency, 391
 epidural analgesia
 initiation, 108
 epidural insertion, 107–08
 esophageal disorders, 377–80
 esophagitis, 377
 esophagus during pregnancy, 375
The Etiology, the Concept and the Prophylaxis of Childbed Fever (Semmelweis), 508
 evaluation of heart during pregnancy, 325
- Fallopio, Gabrielle, 499
 femoral head, osteonecrosis, 289
 fetal alcohol syndrome, 180
 fetal anomalies
 abdominal wall defects, 183, 185
 ambiguous genitalia, 183
 cardiac abnormalities, 182
 chromosomal abnormalities, 179–80
 diagnosis, 184
 gastrointestinal disorders, 183
 genetic screening, 180–81
 hypospadias, 185–86
 infections, 180
 management, 184–85
 meningiomycelocele, 185
 neural tube defects, anencephaly, 181–82
 oral facial defects, 182
 orofacial clefts, 185
 polygenetic, multifactorial disorders, 180
 prevention, 180
 scope of problem, 179

- tetratogenic disorders, fetal alcohol syndrome, 180
 fetal destructive procedures, 505–06
 fetal growth restrictions
 fetal risk factors, 163
 management, Growth Intervention Restriction Trial (GRIT), 164–66
 maternal risk factors, 163
 placental risk factors, 163–64
 fetal heart rate (FHR) monitoring
 ancillary intrapartum testing, STAN, 124
 Category I, 120–21
 Category I FHT management, 122
 Category II, 121
 Category II FHT management, 122–23
 Category III, 121
 Category III FHT management, 123
 devices, 116–17
 EFM nomenclature
 standardization, 117
 NICHD definitions, 117–20
 scope of problem, 116
 special fetal heart tracings, fetal arrhythmias, 121–22
 special fetal heart tracings, sinusoidal FHR, 121
 uterine contraction monitoring, 117
 fetal macrosomia
 diagnosis, 166
 management, 166
 risk factors, 166
 foot pain, 290
 forcep deliveries
 anatomy of forceps, 52
 cesarean section use of forceps, vectis, vacuum, 61–62
 choice of instruments, 52–56
 delivery, 56–58
 indications, 50–51
 rotation of head, 58
 safe delivery requirements, 51
 types, 51–52
 Fracastoro, Girolamo, 507
 Friedman's Curve, 7f. 1.1

 Galen, 499
 gallbladder during pregnancy, 376
 gastroesophageal reflux disease (GERD), 377
 gastrointestinal disorders, 183
 achalasia, 377–78
 acute fatty liver pregnancy (AFLP), 381
 appendicitis, 383
 cholecystitis, 382
 cholelithiasis, 382
 cirrhosis, 381
 colon disorders, 383–84
 colon during pregnancy, 376
 constipation, 383–84
 Crohn's Disease (CD), 383
 esophageal disorders, 377–80
 esophagitis, 377
 esophagus during pregnancy, 375
 gallbladder during pregnancy, 376
 gastroesophageal reflux disease (GERD), 377
 GI tract anatomy, physiology, 375–76
 GI tract diagnostic imaging, procedures in pregnancy, 376–77
 hemorrhoids, 384
 hiatal hernia, 379
 infectious diarrhea, 382
 intrahepatic cholestasis of pregnancy (ICP), 381
 irritable bowel syndrome (IBS), 382–83
 liver disorders, 380–81
 liver during pregnancy, 376
 Mallory-Weiss tears, 379–80
 pancreatitis, 381–82
 peptic ulcer disease (PUD), 377
 scope of problem, 375
 small bowel during pregnancy, 376
 small bowel obstruction, 383
 small intestine disorders, 382
 specific gastrointestinal disorders, evaluation and management, 377
 stomach during pregnancy, 376
 ulcerative colitis (UC), 384
 viral hepatitis, 380
 genetics
 aneuploidy, second trimester US markers, 157
 cell free DNA testing (cf-DNA), 157–59
 chromosomes, 151
 genetic screening, definitive testing, 153–54
 genetic terminology, 151–52
 invasive screening, 157–59
 multifactorial conditions, 152–53
 multifactorial inheritance, molecular biology, 152
 scope of problem, 150–51
 screening tests, analyte screening, 155–56
 screening tests, elevated MSAFP, 156
 screening tests, population screening, 154–55
 tools for patient care, counseling, 150
 ultrasound screening, 156–57
 GI tract anatomy, physiology, 375–76
 GI tract diagnostic imaging, procedures in pregnancy, 376–77
 Goodpasture's syndrome, 337

 great vessels transposition, impaired systemic right ventricle, 328
 group B streptococcus (GBS), 200–1
 Growth Intervention Restriction Trial (GRIT), 164–66
 Guillain-Barré, 353

 hallucinogens, 475
 headache, tension-type, 347
 hematological diseases
 anemia, 367–68
 coagulation factors, effect of pregnancy on, 367
 disseminated intravascular coagulation, 373–74
 inherited bleeding disorders, 373
 physiologic changes, 366–67
 prophylactic anticoagulation, 370–71
 scope of problem, 366
 thrombocytopenia, 368–70
 thrombophilia, 371–72
 thrombosis, 370–71
 hemodynamic adaptations to pregnancy, 325
 hemorrhagic stroke, 345–47
 hemorrhoids, 384
 hemotologic malignancies
 epidemiology, 482
 lymphoma treatment, 482
 treatment, 482
 hiatal hernia, 379
 hip joint pain, 289–90
 Hippocrates, 498
Histoire des Accouchements chez tous les Peuples (Witkowski), 498
 Hodge, Hugh, 507
 Holmes, Oliver Wendell, Sr., 508
 Hôtel-Dieu, 500–02
 human immunodeficiency virus (HIV)
 patient factors, repeat third trimester testing, 443
 perinatal transmission, barriers to further reductions, 443
 scope of problem, 442
 screening, 442–44
 human immunodeficiency virus (HIV), antepartum care
 antiviral therapy, 446–48
 counseling, 446
 delivery plan, 448–49
 laboratory monitoring, vaccines, 448
 risk factors, testing, 445–46
 human immunodeficiency virus (HIV), intrapartum care
 cesarean delivery, 449
 preterm labor, 449
 treatment, 449
 vaginal delivery, 449

Index

- human immunodeficiency virus (HIV), post-partum care
 breast feeding, 450
 infant testing, 450
 infant treatment, 450
 maternal follow-up, 451
 post-partum hemorrhage, 450
 human immunodeficiency virus (HIV), preconception care
 contraception, 444–45
 counseling, 445
 preconception goals, 445
 serodiscordant couples, conception, 445
 Hunter, William, 500
 hyperemesis gravidarum, nausea and vomiting of pregnancy
 diagnosis, clinical course, 308–10
 differential diagnosis, 308–09
 etiology theories, 309
 inpatient therapy, 311–12
 laboratory abnormalities, 310
 pharmacological interventions, 310–11
 psychologic component, 312
 scope of problem, 308
 standard evaluation parameters, 310
 transient hyperthyroidism associated, 310
 treatment, non-pharmacological interventions, 310
 hyperparathyroidism, 390–91
 hypertension
 chronic hypertension, superimposed preeclampsia, 319–20
 future implications, 321–22
 gestational, pregnancy induced hypertension, 315–16
 new onset postpartum hypertension, differential diagnosis, 321
 oral hypertension agents, 321t. 35.2
 postpartum hypertension, 320–21
 preeclampsia, severe features, 317
 preeclampsia, fetal manifestations, 317
 preeclampsia-eclampsia, 316
 pregnancy related risk factors, 316
 scope of problem, 315
 superimposed preeclampsia, risk factors, 320
 hyperthyroidism, 388–89
 hypoparathyroidism, 391
 hypopituitarism causes, 392
 hypothyroidism, 387–88
 hypospadias, 185–86
 idiopathic intracranial hypertension, pseudomotor cerebri, 348
 infectious diarrhea, 382
 infectious diseases
 bacterial vaginosis, 439
 chlamydia trachomatis, neisseria gonorrhea, 437–38
 Coxsackie virus, 437
 Dengue virus (DENV), 436–37
 Epstein-Barr virus (EBV), 437
 hepatitis, 434–35
 hepatitis E, 433
 herpes simplex virus (HSV), 438
 human papilloma virus, 439
 infectious diarrhea, 382
 influenza, 432–33
 Lyme disease, 439
 malaria, 433
 measles, 436
 parvovirus B19, 436
 pelvic inflammatory disease, 438
 Rocky Mountain spotted fever (RMSF), 439–40
 rubella, 436
 scope of problem, 432
 sexually transmitted diseases, 437–39
 syphilis, 438
 tick-borne bacterial diseases, 439–40
 trichomonas vaginalis, 438–39
 tuberculosis (TB), 440
 urinary tract infections, 433
 vaccine-preventable disease, 440
 varicella zoster (Chickenpox), 435–36
 West Nile Virus (WNV), 437
 Zika virus, 437
 infectious diseases, more serious for fetus vs. mother
 cytomegalovirus (CMV), 433–34
 listeria monocytogenes, 434
 toxoplasma gondii, 434
 influenza, 334, 432–33
 inhalants, 475
 inhallational analgesia, Etonox, 105–06
 inherited bleeding disorders, 373
 inherited lesions
 bicuspid aortic valve and aortic stenosis, 328
 Marfan syndrome, 328
 intraamniotic infection, chorioamnionitis
 clinical signs, symptoms, 198
 common organisms found, amniotic fluid, 197
 diagnosis approach, 197–98
 fetal outcome, 200
 group B streptococcus (GBS), 200–01
 management, 199–200
 maternal outcome, 200
 prevention, 200
 scope of problem, 197
 intracardiac communications, 327
 intrahepatic cholestasis of pregnancy (ICP), 381
 intrahepatic cholestastis, 427–28
 intra-partum pulmonary complications
 air embolism, 341
 amniotic fluid embolism, 339
 aspiration pneumonitis, 339–40
 pneumothorax, subcutaneous emphysema, 340–41
 pulmonary edema (PE), 340
 irritable bowel syndrome (IBS), 382–83
 ischemic stroke, 344–45
 IUGR, symmetric vs. asymmetric, 164
 knee pain, 290
 labor, abnormal
 active phase labor, 15–16
 active phase labor, disorders and treatments, 16–17
 active phase labor, protraction of labor treatment, 17
 active phase labor arrest, 17–18
 dysfunctional labor patterns, 13
 first and second stage, labor practices affecting duration, 19–20
 latent phase, 13–14
 latent phase, disorders and treatment, 14–15
 scope of problem, 13
 second stage disorders, 18–19
 spontaneous labor at term, duration, 15
 labor, induction and augmentation
 amniotomy, 27–28
 augmentation in laboring patient, 29
 Bishop scoring system, 25t. 3.1
 cervical ripening, 24
 cervical ripening, methods, 24–27
 cervical ripening, prostaglandins, 24–25
 gestational age determination, criteria, 24
 goal of, 23
 hygroscopic dilators, 26
 intracervical foley catheter, 25–26
 labor induction, favorable cervix, 27
 maternal, fetal conditions, 24
 membrane stripping, 26
 nipple stimulation, 26
 nitric oxide donors
 medications, 26–27
 oxytocin, 27
 rate of induction, 23
 scope of problem, 23
 special situations, elective induction after 39 weeks gestation, 28
 special situations, intrauterine fetal demise, 29

- special situations, other risk factors, 28
 special situations, premature
 ruptured membranes, 28–29
 special situations, prior cesarean, 28
 labor, normal
 cardinal movements of labor,
 descent, 6
 cardinal movements of labor,
 engagement, 4–6
 cardinal movements of labor,
 expulsions, 6
 cardinal movements of labor,
 extension, 6
 cardinal movements of labor,
 external rotation, 6
 cardinal movements of labor,
 flexion, 6
 cardinal movements of labor,
 internal rotation, 6
 delivery of fetus, 9–10
 diagonal conjugate, 5
 female bony pelvis components,
 5
 fetal presentations, positions, 4
 labor hormonal physiology, 1–2
 labor mechanics, 2–3
 labor progress, 5–8
 midpelvis, 5
 obstetric conjugate, 5
 passenger, fetal attitude, 3
 passenger, fetal lie, 3
 passenger, fetal position, 3
 passenger, fetal presentation, 3
 passenger, fetal size, 3
 passenger, fetal station, 3
 pelvic inlet, 5
 pelvic outlet, 5–4
 pelvis, pelvic assessment, 3, 4
 power, uterus, 2–3
 process, stages overview, 1
 scope of problem, 1
 second stage of labor, 8–9
 third stage of labor, 10
 labor pain physiology
 first stage of labor, 106–07
 second stage of labor, 107
 lamotrigine, 461
 legs cramps, 290
 lipid disorders, 396
 listeria monocytogenes, 434
 lithium, 461
 liver disorders, 380–81
 liver during pregnancy, 376
 lower extremity pain, 290
 lung cancer, 341
 Lyme disease, 439
 lymphocytic hypophysitis, 392
 malaria, 433
 Mallory-Weiss tears, 379–80
 malpresentation
 breech presentation, 188–92
 breech presentation, criteria
 indicated for institutions, 191
 brow presentation, 194
 compound presentation, 194–95
 face presentation, 193–94
 occiput posterior, 192–93
 occiput transverse, 193
 scope of problem, 188
 transverse lie, 194
 vaginal breech delivery
 technique, 192
 Marfan syndrome, 329, 419
 antepartum management, 419
 inherited lesions, 328
 postpartum considerations, 419
 preconception, 419
 treatment and medications, 419
 marijuana, 473
 effects in pregnancy and
 newborn, 473
 ingestion methods, 473
 screening, 473
 synthetic cannabinoids, 473
 THC effects, 472
 treatment, 474
 maternal mortality associated with
 pregnancy, 326t. 36.2
 Mauriceau, François, 502
 measles, 334, 436
 median neuropathy, carpal tunnel
 syndrome, 291
 medication overuse headache, 349
 meningocele, 185
 Mercurio, Scipione, 499
 Middle East respiratory syndrome, 334
 midwifery delivery, women, 498
 migraine, 347–48
Milestones in Midwifery (Radcliffe), 502
 monoamniotic twin gestation, 206
 monochorionic gestations, 205
 mood stabilizers and
 anti-epileptics, 462
 morbidly adherent placenta (MAP), 36
 complications, 36
 management, 36–38
 multifetal pregnancy
 abbreviations, 205
 associated reproductive technology
 (ART), maternal fetal risks, 207–08
 conjoined twins, 207
 demise of co-twin in monochorionic
 gestation, 207
 fetal anomalies, 205
 fetal risks, 205
 higher order multiples, 210–11
 labor, delivery considerations, 210
 maternal risks, 207
 monoamniotic twin gestation, 206
 monochorionic gestations, 205
 preterm labor management, 209
 preterm premature rupture of
 membranes (PPROM), 209
 scope of problem, 204
 time of delivery, uncomplicated
 gestations, 210
 twin anemia polycythemia arterial
 sequence (TAPS), 205
 twin reversed arterial perfusion
 (TRAP), 206–07
 twin-twin transfusion syndrome
 (TTTS), 205
 zygosity/chorionicity/
 epidemiology, 204–05
 multifetal pregnancy, antenatal care
 maternal nutrition, physiology, 208
 maternal weight gain, 208
 multifetal pregnancy, antenatal testing
 dichorionic/diamniotic
 gestations, 210
 monochorionic gestations, 210
 multifetal pregnancy, antepartum
 considerations
 aneuploidy screening, 209
 death of one fetus, second and third
 trimester loss, 210
 death of one fetus, vanishing
 twin, 210
 discordant fetal growth, 209–10
 multifetal pregnancy, antepartum
 management
 preterm birth prevention, 208–09
 preterm birth risk prevention, 208
 multifetal pregnancy, early gestation
 management high order multiples
 multifetal reduction, 209
 selective termination, 209
 multiple sclerosis (MS), 352, 496
 postpartum and lactation, 351
 treatment during pregnancy, 351
 musculoskeletal disorders
 abdominal wall laxity, 291–92
 chest, abdominal pain, 291–92
 desmoid tumors, fibromatosis, 292
 femoral head, osteonecrosis, 289
 foot pain, 290
 hip joint pain, 289–90
 knee pain, 290
 legs cramps, 290
 lower extremity pain, 290
 median neuropathy, carpal tunnel
 syndrome, 291
 myofascial pain, 293
 osteitis pubis, 288
 painful rib syndrome, 292
 patellofemoral pain syndrome, 290
 pelvic girdle pain, 287–89
 public osteomyelitis, 288
 public symphyseal separation, 288

Index

- musculoskeletal disorders (*Cont.*)
 round ligament pain, 288–89
 sacroiliac joint pain,
 dysfunction, 287–88
 scope of problem, 286–87
 soft tissues, 293
 stenosing tendiopathy, 291
 thigh pain, 290
 thoracic outlet syndrome (TOS), 292
 transient osteoporosis, 289–90
 ulnar neuropathy, cubital tunnel
 syndrome, 291
 umbilical pain, 292
 upper extremity pain, 291
 myasthenia gravis (MG), 351
 basic evaluation, 352
 crisis types, 352
 labor in MG patients, 352–53
 management, 352
 treatment, 352
 myocardial infarction (MI), 328
 myofascial pain, 293
- Naegle, Franz, 506
 National Collaborative Perinatal
 Project, 8
 nausea, vomiting of pregnancy
 See hyperemesis gravidarum, nausea
 and vomiting of pregnancy
 nephrolithiasis, 360
 neural tube defects,
 anencephaly, 181–82
 neurological disease
 acute onset neurological signs,
 symptoms, 345f. 38.1
 acute stroke, differential
 diagnosis, 346
 cerebrovascular disease, 344
 cerebrovascular events in pregnancy,
 preexisting factors, 346
 headache, tension-type, 347
 hemorrhagic stroke, 345–47
 idiopathic intracranial hypertension,
 pseudomotor cerebri, 348
 ischemic stroke, 344–45
 medication overuse headache, 349
 migraine, 347–48
 multiple sclerosis (MS), 351
 multiple sclerosis (MS), postpartum
 and lactation, 351
 multiple sclerosis (MS), treatment
 during pregnancy, 351
 myasthenia gravis (MG), 351–52
 myasthenia gravis (MG), basic
 evaluation, 352
 myasthenia gravis (MG), crisis
 types, 352
 myasthenia gravis (MG), labor in
 MG patients, 352–53
- myasthenia gravis (MG),
 management, 352
 myasthenia gravis (MG),
 treatment, 352
 neuropathies, Bell's palsy (BP), 353
 neuropathies, Guillain-Barré, 353
 new headache algorithm, 345f. 38.2
 postpartum headache, 348
 scope of problem, 344
 secondary headache, 349
 seizure, anticonvulsant levels,
 physiological changes in
 pregnancy, 350
 seizure, antiepileptic medication
 considerations, 350
 seizure, life-threatening causes, 349
 seizure algorithm, 346f. 38.3
 seizure disorder patients,
 management during
 pregnancy, 350
 seizure disorder patients,
 postpartum management, 350–51
 seizure disorder patients,
 preconception care, 349
 seizure disorders, 349–51
 seizure disorders, preconception
 plan, 349
 trigeminal autonomic
 cephalalgias, 348
 neuropathies
 Bell's palsy (BP), 353
 Guillain-Barré, 353
 new headache algorithm, 345f. 38.2
 non-immune hydrops fetalis (NIHF).
 See alloimmunization, non
 immune hydrops fetalis
 non-pharmacological analgesia in
 labor, 105
 normal labor. *See* labor, normal
 normal placenta, 32
 normal pregnancy vs. heart failure,
 325t. 36.1
 normal skin changes, 424
- obesity
 BMI classification, World Health
 Organization, 297t. 33.1
 delivery preparedness, 301
 equipment, supplies useful in care,
 301t. 33.3
 etiology, 296–97
 gastric bypass, 303
 gestational weight gain, 298–99
 intraoperative
 considerations, 301–02
 intrapartum, 300–01
 macronutrients caloric value, 297t.
 33.2
 postpartum period, 302–03
 preconception considerations, 297–98
- scope of problem, 296
 second trimester, special
 considerations, 299–300
 third trimester, special
 considerations, 300
 ob-gyn role, screening and
 treatment, 454
 obliquely contracted (rachitic pelvis),
 506505f. 53.9
The Obliquely contracted Pelvis
 (Naegle), 506
Observations (Bourgeois), 501
 obsessive-compulsive disorder (OCD)
 disorder, 459–60
 obstetric anesthesia. *See* anesthesia
 obstetric ultrasound
 first trimester, AIUM
 indications, 128–31
 safety, 127
 scope of problem, 126–27
 second trimester, AIUM
 indications, 129–41
 terminology, 127–28
 third trimester, AIUM indications,
 132, 136–38
 obstetrics, history
 cesarean delivery, 506–07
 Chamberlen family, 502–05
 early beginnings, 498
 fetal decapitation device, 506f. 53.9
 Middle Ages, 498–99
 pre-eclampsia, 508
 pueral sepsis, 507–08
 the Renaissance, 499
 Soranus of Ephesus, 498
 term origins, 498
 women and, 498
 operative vaginal delivery
 cesarean section use of forceps,
 vectis, vacuum, 61–62
 forcep deliveries, delivery, 56–58
 forcep deliveries, rotation of
 head, 58
 forcep deliveries, types, 51–52
 forecep deliveries, anatomy of
 forceps, 52
 forecep deliveries, choice of
 instruments, 52–56
 indications, 50–51
 safe delivery requirements, 51
 scope of problem, 50
 vacuum deliveries, 59–60
 vacuum deliveries, application of
 vacuum, 60–61
 vacuum deliveries, choice of
 instruments, 60
 vacuum deliveries, delivery, 61
 opiate abuse
 buprenorphine implant, 472
 buprenorphine treatment, 471–72

- community resources, 472
- diagnosis, 470
- epidemiology, 469
- screening, 470
- short/long term effects, 470
- treatment, 470–71
- opiates abuse, 469
- opioids. *See also* substance abuse
 - meperidine, 106
 - patient-controlled analgesia (PCA), 106
- oral facial defects, 182
- orofacial clefts, 185
- osteitis pubis, 288
- osteogenesis imperfecta (OI)
 - antepartum management, 421
 - labs, 420
 - postpartum considerations, 421
 - preconception, 420
 - treatment and medications, 421
- osteoporosis, 391–92
- ovarian cancer
 - diagnosis, 482
 - epidemiology, 481–82
- painful rib syndrome, 292
- pancreatitis, 381–82
- Paré, Ambrose, 501
- parvovirus B19, 436
- patellofemoral pain syndrome, 290
- patient consent, in labor, 107
- pelvic, horseshoe kidney, 357–58
- pelvic girdle pain, 287–89
- pelvic hematomas. *See* perineal
 - trauma, third and fourth degree lacerations, hematomas
- pelvic inflammatory disease, 438
- pemphigoid gestationis, 426–27
- peptic ulcer disease (PUD), 377
- perinatal depression
 - DSM-5 criteria for peripartum major depression onset, 456
 - DSM-5 description, 455
 - generalized anxiety components, 457
 - perinatal anxiety, 456–57
 - risk factors, 455
 - treatment, 456
- perineal trauma, third and fourth degree lacerations, pelvic hematomas
 - external anal sphincter repair, 100
 - external anal sphincter repair, end to end, 100
 - external anal sphincter repair, overlapping repair, 100–01
 - identification, 99
 - pelvic hematomas, 102–03
 - postpartum care, complications, 102
 - repair, 99
 - repair, surgical equipment, 100
 - scope of problem, 99
- peripartum cardiomyopathy (PPCM), 329
- pheochromocytoma, 394–95
- pituitary insufficiency, 392
- placenta abruption
 - defined, 247
 - diagnosis, 247–48
 - outcomes, 248
 - risk factors, 247
- placenta accreta
 - diagnosis, 247
 - outcomes, 246, 247
 - risk factors, 246
- placenta previa
 - classification, 246
 - defined, 245
 - diagnosis, 245–46
 - outcomes, 246
- placenta previarisk factors, 245
- placental abnormalities
 - chorioangioma, 38
 - chorioangioma, complications, 39
 - chorioangioma, management, 39
 - circumvallate placenta, 38
 - circumvallate placenta, complications, 38
 - circumvallate placenta, management, 38
 - morbidly adherent placenta (MAP), 36
 - morbidly adherent placenta (MAP), complications, 36
 - morbidly adherent placenta (MAP), management, 36–38
 - normal placenta, 32
 - scope of problem, 32
 - succenturate lobe, 35
 - succenturate lobe, complications, 35
 - succenturate lobe, management, 35
 - vasa previa, 34
 - vasa previa, complications, 34–35
 - vasa previa, management, 35
 - velamentous cord insertion, complications, 33
 - velamentous cord insertion, prenatal management, 33–34
- polygenetic, multifactorial disorders, 180
- polymorphic eruption, pruritic urticarial papules and plaques of pregnancy (PUPPP), 425–26
- polymyositis, dermatomyositis, 418
- post term pregnancy
 - dysmaturity, 280
 - fetal distress, oligohydramnios, 280
 - fetal growth restriction, 280
 - incidence, 279–80
 - intrapartum management, 283
 - long term sequelae, 283
 - macrosomia management, 281–83
 - management, evaluation, testing, 280–81
 - oligohydramnios management, 283
 - placental dysfunction, 280
 - postmaturity syndrome, 280
 - scope of problem, 279–80
 - sequelae, 280
 - ultrasonography dating accuracy, 280t. 31.1
- postpartum headache, 348
- postpartum hemorrhage
 - antibiotics, 263–64
 - blood replacement products, 259
 - breast abscess, 265
 - definition, etiology, 252
 - early recognition, risk assessment, 253–54
 - endometritis, 264–65
 - fluid management, 264
 - incidence, 252
 - initial evaluation, 255
 - mastitis, 265
 - maternal physiology, 252–53
 - medical management, 255–56
 - postnatal sepsis, causes, 264
 - prevention, 254–55
 - quality improvement programs, 259
 - related special circumstances, 257–59
 - risk factors, 253
 - scope of problem, 252
 - septic pelvic thrombophlebitis (SPT), 266–67
 - special therapeutic options, 257
 - surgical management, 256–57
 - surgical site, wound infections, 266
 - tamponade techniques, 256
 - urinary tract infections, 265–66
- postpartum infection
 - clinical management, 263
 - definitions, 262–63
 - risk factors, 263
 - scope of problem, 262
 - sepsis six care bundle, 263
 - sequential organ failure assessment (SOFA), 262
 - systemic inflammatory response syndrome (SIRS), 262–63
- postpartum psychosis
 - antipsychotics, 462
 - electroconvulsive therapy (ECT), 462
 - lamotrigine, 461
 - lithium, 461
 - mood stabilizers and anti-epileptics, 462
 - psycopharmacological treatment, 461

Index

- postpartum psychosis (*Cont.*)
 risk factors, 460
 post-partum thyroiditis (PPT), 389–90
 posttraumatic stress disorder (PTSD), 458
 risk factors, 459
 treatment, 459
 Pott's Disease, 506
 preeclampsia, hemolysis-elevated liver enzymes-low platelets (HELLP) syndrome, 359
 pregnancy after lung replacement surgery, 341
 premature rupture of membranes (PROM)
 before 24 weeks gestation, 216
 at 24–34 weeks gestation, 216
 at 34–37 weeks gestation, 215–16
 diagnosis of, 214–15
 etiology, 214
 management, 215
 management, by gestational age, 217
 patient induction, 216–17
 preterm premature rupture of membranes, 213–14
 previable premature rupture of membranes, 213–14
 scope of problem, 213
 special circumstances, cervical cerclage in place, 217
 special circumstances, herpes simplex virus, 217
 special circumstances, human immunodeficiency virus, 218
 special circumstances, patients with history of PROM, 217
 special circumstances, second trimester amniocentesis, 217
 term premature rupture of membranes, 213
 prenatal diagnosis
 cell-free fetal DNA (cfDNA)
 testing, 144–45
 congenital infections, cytomegalovirus (CMV)
 management, 147–48
 counseling, 143
 cystic fibrosis (CF), 145
 Eastern European Jewish descent, genetic diseases screening, 145
 first trimester biochemical screen, 144
 first trimester ultrasound, Nuchal translucency, 144
 FISH, CMA, 147
 invasive options, amniocentesis, 147
 invasive options, CVS, 147
 invasive testing, CVS, amniocentesis, 144
 multiple gestations factors, 147
 scope of problem, 143
 second trimester, maternal serum screen (quad marker screen), 145–46
 second trimester abnormal serum markers, b-hCG, 147
 second trimester abnormal serum markers, msAFP, 146
 ultrasound markers for abnormalities, omphalocele and gastroschisis, 146
 ultrasound markers for abnormalities, Trisomy 21, 146
 unconjugated estriol, 147
 preterm delivery
 cerclage placement criteria, 222
 defined, categories, diagnosis, 220
 factors associated with, 221
 magnesium sulfate therapy
 indications, 225
 management, 222–25
 pathogenesis, 221
 prediction, prevention, 222
 scope of problem, 220–21
 screening, prevention, 221–22
 tocolytic therapy contraindications, 225
 preterm premature rupture of membranes (PPROM), 209
 primary hyperaldosteronism, 395
The Principles and Practice of Obstetrics (Hodge), 507
 prolactinomas, 392–93
 prophylactic anticoagulation, 370–71
 prurigo, 429
 pruritic folliculitis, 429
 psychiatric diseases, pregnancy and postpartum period
 baby blues, 454–55
 baby blues, risk factors, 455
 baby blues, treatment, 455
 bipolar disorder, 457–58
 bipolar disorder, pharmacological treatment, 458
 bipolar disorder, risk factors, 457–58
 bipolar disorder, treatment, 458
 ob-gyn role, screening and treatment, 454
 obsessive-compulsive disorder (OCD) disorder, 459–60
 perinatal depression, 455
 perinatal depression, DSM-5 criteria for peripartum major depression onset, 456
 perinatal depression, DSM-5 description, 455
 perinatal depression, generalized anxiety components, 457
 perinatal depression, perinatal anxiety, 456–57
 perinatal depression, risk factors, 455
 perinatal depression, treatment, 456
 postpartum psychosis, 460–61
 postpartum psychosis, antipsychotics, 462
 postpartum psychosis, electroconvulsive therapy (ECT), 462
 postpartum psychosis, lamotrigine, 461
 postpartum psychosis, lithium, 461
 postpartum psychosis, mood stabilizers and anti-epileptics, 462
 postpartum psychosis, psychopharmacological treatment, 461
 postpartum psychosis, risk factors, 460
 posttraumatic stress disorder (PTSD), 458
 posttraumatic stress disorder (PTSD), risk factors, 459
 posttraumatic stress disorder (PTSD), treatment, 459
 registries, resources for perinatal clinicians, 462
 scope of problem, 454
 public osteomyelitis, 288
 public symphyseal separation, 288
 pulmonary disease
 acute, chronic respiratory health assessment, 332
 acute chest syndrome (ACS), 337–38
 asthma symptoms and, 336
 baseline pulmonary parameters, 333
 bronchiectasis, 338
 cystic fibrosis (CF) and, 335
 escalation of care parameters, 333
 Goodpasture's syndrome and, 337
 intra-partum pulmonary complications, air embolism, 341
 intra-partum pulmonary complications, amniotic fluid embolism, 339
 intra-partum pulmonary complications, aspiration pneumonia, 339–40
 intra-partum pulmonary complications, pneumothorax, subcutaneous emphysema, 340–41
 intra-partum pulmonary complications, pulmonary edema (PE), 340
 lung cancer, 341
 Middle East respiratory syndrome, 334
 pregnancy after lung replacement surgery, 341
 pulmonary hypertension (PH), 338

- pulmonary infectious diseases,
 bacterial pneumonia
 (CABP), 333–34
 restrictive pulmonary disease, 337
 scope of problem, 332
 smoking in pregnancy, 339
 Systemic Inflammatory Response
 Syndrome (SIRS), 336–37
 viral pneumonias,
 chickenpox, 334–35
 viral pneumonias, influenza, 334
 viral pneumonias, measles, 334
 viral pneumonias, Middle East
 respiratory syndrome, 334
 viral pneumonias, pulmonary
 tuberculosis (PTB), TB
 screening, 335
 pulmonary hypertension (PH), 338
 pulmonary hypertensions,
 Eisenmenger's syndrome, 327
 pulmonary infectious diseases,
 bacterial pneumonia
 (CABP), 333–34
 pulmonary tuberculosis (PTB), TB
 screening, 335
- Radcliffe, Walter, 502
 regional analgesia
 anesthesia risks, 106
 side effects, accidental intravenous
 injection, 109–10
 side effects, hypotension, 109
 side effects, neurological
 damage, 110
 side effects, obstetric outcomes
 effect, 110
 side effects, total spinal, 109
 side effects, unilateral or partial
 blockade, 109
 regional anesthesia
 contraindications, 108
 indications, 107
 special circumstances, 108
 renal diseases
 acute fatty liver of pregnancy
 (AFLP), 359
 acute kidney injury (AKI), 355,
 358–59
 acute kidney injury (AKI),
 diagnosis, 359
 acute kidney injury (AKI), general
 management, 359
 antiphospholipid Syndrome
 (APS), 362–63
 asymptomatic bacteriuria, acute
 cystitis, pyelonephritis, 360–61
 autosomal dominant polycystic
 kidney disease (ADPKD), 363–64
 chronic glomerulonephritis, 363
 chronic hypertension, 361
 chronic kidney disease antepartum
 evaluation, fetal surveillance,
 postpartum care, 361
 chronic renal diseases, 355
 diabetic nephropathy, 362
 diagnostic, laboratory
 evaluation, 355–56
 diagnostic imaging, 357
 dialysis dependent chronic renal
 failure, 363
 medications, teratogenicity, 364
 nephrolithiasis, 360
 normal renal adaptations to
 pregnancy, 355–56
 pelvic, horseshoe kidney, 357–58
 preeclampsia, hemolysis-elevated
 liver enzymes-low platelets
 (HELLP) syndrome, 359
 renal malignancy, 363
 renal transplant, 361–62
 scope of problem, 355
 solitary kidney, 357
 systemic lupus erythematosus
 (SLE), 362
 thrombotic thrombocytopenic
 purpura, atypical hemolytic
 uremic syndrome, 359–61
 renal malignancy, 363
 renal transplant, 361–62
 restrictive pulmonary disease, 337
 rheumatoid arthritis (RA)
 antepartum management, 416
 breastfeeding, 495
 classification criteria, 495
 contraception, 495
 labs, 416
 postpartum considerations, 416–17
 preconception, 415–16
 treatment and medications, 416
- Rigby, Edward, 507
 Rocky Mountain spotted fever
 (RMSF), 439–40
 Rosengarten (Rösslin), 498
 Rösslin, Eucharis, 498
 round ligament pain, 288–89
 Rousett, Francios, 506
 Royal College of Physicians, 504
 rubella, 436
 Rubin's, Woods corkscrew, 89–90
- sacroiliac joint pain,
 dysfunction, 287–88
 Sängner, Max, 507
 scleroderma
 antepartum management, 417–18
 labs, 417
 postpartum considerations, 418
 preconception, 417
 treatment and medications, 418
 scope of problem, 344
- second trimester pregnancy loss.
See also third trimester fetal loss
 antiphospholipid antibody
 syndrome (APS), 230
 cervical insufficiency, 229
 congenital anomalies, 229
 diagnosis, vital signs, physical
 exam, 231
 etiology, 229
 genetic causes, 231
 infections, 230
 laboratory studies, 231–32
 management, 232–33
 placenta causes, 230–31
 presentation, 231
 scope of problem, 229
 stillbirth worksheet, 233t. 25.1
 subsequent pregnancy
 recommendations, 233–34
 secondary headache, 349
The Secret Instrument
 (Radcliffe), 502
 seizure, seizure disorders
 anticonvulsant levels, physiological
 changes in pregnancy, 350
 antiepileptic medication
 considerations, 350
 life-threatening causes, 349
 patients, management during
 pregnancy, 350
 patients, postpartum
 management, 350–51
 patients, preconception care, 349
 preconception plan, 349
 Semmelwies, Ignaz, 508
 sepsis. *See* postpartum infection
 septic pelvic thrombophlebitis, 74
 sexually transmitted diseases, 437–39
 Sheehan syndrome, 392
 shoulder dystocia
 abdominal rescue, 91
 BE CALM, 95
 documentation, 93
 Gaskin maneuver, 90
 HELPER, 95
 internal clavicle fracture, 91
 management, 91–93
 maternal complications, 86
 McRoberts' maneuver, 88
 newborn complications, 87
 posterior arm delivery, 89–91
 posterior axially traction, 90–92
 risk factors, 87–88
 rotational maneuvers. Rubin's,
 Woods corkscrew, 89–90
 scope of problem, 86
 simulation, 94–97
 subsequent pregnancies
 management, 93–94
 suprapubic pressure, 88, 89

Index

- shoulder dystocia (*Cont.*)
 symphysiotomy, 91
 Zavanelli maneuver, 91
- Sjögren's syndrome
 antepartum management, 415
 labs, 415
 postpartum considerations, 415
 preconception, 414–15
 treatment and medication, 415
- small bowel during pregnancy, 376
- small bowel obstruction, 383
- small intestine disorders, 382
- SMFM. *See* Society for Maternal Fetal Medicine
- smoking in pregnancy, 339
- Society for Maternal Fetal Medicine (SMFM), 8
- soft tissues pain, 293
- solitary kidney, 357
- Soranus of Ephesus, 498
- specific hormones, effects of pregnancy on, 396
- spinal cord injury (SCI), 492
 autonomic hyperreflexia, 493
 contraception, 494
 debubitus ulcers, 493
 labor and delivery issues, 493–94
 sexual issues, 494
 urinary tract infections, 494
- stenosing tendiopathy, 291
- stimulants, 474–75
- stimulants abuse
 screening, 475
 treatment, 475
- stomach during pregnancy, 376
- substance abuse
 addiction neurobiology, 465
 addiction stages, 466
 alcohol abuse, background/
 epidemiology, 466–67
 alcohol abuse, diagnosis, 467
 alcohol abuse, screening, 467
 alcohol abuse, treatment, 467
 ancillary resources, 466
 breastfeeding by patients, 475–76
 hallucinogens, 475
 inhalants, 475
 marijuana, 472–73
 marijuana, effects in pregnancy and newborn, 473
 marijuana, ingestion methods, 473
 marijuana, screening, 473
 marijuana, synthetic cannabinoids, 473
 marijuana, THC effects, 472
 marijuana, treatment, 474
 obstetrical care, 465
 opiates, 469
 opiates, buprenorphine implant, 472
 opiates, buprenorphine
 treatment, 471–72
 opiates, community resources, 472
 opiates, diagnosis, 470
 opiates, epidemiology, 469
 opiates, screening, 470
 opiates, short/long term effects, 470
 opiates, treatment, 470–71
 patient psychosocial issues, 466
 scope of problem, 465
 screening tools, 467
 stimulants, 474–75
 stimulants, screening, 475
 stimulants, treatment, 475
 tobacco, adverse effects, 468
 tobacco, adverse effects on pregnancy, 468
 tobacco, diagnosis, 468
 tobacco, epidemiology, 467
 tobacco, FDA approved medications, 468
 tobacco, other substance abuse and, 469
 tobacco, relapse risk, 469
 tobacco, screening, 467
 tobacco, treatment, 468–69
- succentrate lobe
 complications, 35
 management, 35
- syphilis, 438
- A System of Midwifery* (Rigby), 507
- Systemic Inflammatory Response Syndrome (SIRS), 336–37
- systemic inflammatory response syndrome (SIRS), 262–63
- systemic lupus erythematosus (SLE), 415
 antepartum management, 412–13
 labs, 412
 postpartum considerations, 413–14
 preeclampsia vs. lupus nephritis, 413
 preconception, 412
 treatment and medications, 413
- systemic lupus erythematosus (SLE), 362
- Tetralogy of Fallot (TOF), 328
- tetratogenic disorders, fetal alcohol syndrome, 180
- thigh pain, 290
- third trimester fetal loss
 diagnosis, 236–37
 future pregnancies, 242–43
 history, physical exam of patient, 238
 laboratory evaluation, 238–40
 maternal history after stillbirth, 238
 pathology evaluation, 240–41
 psychosocial ramifications, 241–42
 risk factors, 237–38
 scope of problem, 236
 treatment, 241
- thoracic outlet syndrome (TOS), 292
- thrombocytopenia, 368–70
- thromboembolism, 72–73
- thrombophilia, 371–72
- thrombosis, 370–71
- thrombotic complications
 delivery complications, 488
 diagnosis, 486–87
 other considerations, 489
 physiology, 485
 risk factors, 485–86
 scope of problem, 485
 thromboprophylaxis, 488–89
 treatment, 487–88
- thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, 359–61
- thyroid disease, 387
- thyroid nodules, 390
- tick-borne bacterial diseases, 439–40
- tobacco abuse
 adverse effects, 468
 adverse effects on pregnancy, 468
 diagnosis, 468
 epidemiology, 467
 FDA approved medications, 468
 other substance abuse and, 469
 relapse risk, 469
 screening, 467
 treatment, 468–69
- toxoplasma gondii, 434
- Traité des Maladies des Femmes Grosses et Accouchées* (Mauriceau), 502
- Traité Nouveau de l'Hystérotomotomie ou l'Enfantement Césarien I* (Roussett), 506
- transcutaneous electrical nerve stimulation (TENS), 105
- transient osteoporosis, 289–90
- trauma. *See also* perineal trauma, third and fourth degree lacerations, pelvic hematomas
 abdominal, gastrointestinal
 changes management, 271
 advanced life support, 273f. 30.2
 airway, respiratory changes management, 270
 blunt trauma, 275–76
 burns, 276
 cardiac arrest management, 272–74
 cardiovascular, hematologic changes management, 270–71
 cesarean delivery complications, fetal and neonatal risks, 76
 domestic, sexual abuse, 276
 effects on pregnancy, 276–77
 emergency cesarean section, 277
 fetal monitoring, 275
 penetrating trauma, 276

- peri-mortem cesarean section, 273–74
- pregnancy changes, management, 270
- pregnancy imaging, 271–72
- prehospital care principles, 272
- primary survey, pregnant trauma patients, 275
- renal, pelvic changes management, 271
- scope of problem, 269–70
- trichomonas vaginalis, 438–39
- trigeminal autonomic cephalalgias, 348
- tuberculosis (TB), 440
- twin anemia polycythemia arterial sequence (TAPS), 205
- twin reversed arterial perfusion (TRAP), 206–07
- twin-twin transfusion syndrome (TTTS), 205
- ulcerative colitis (UC), 384
- ulnar neuropathy, cubital tunnel syndrome, 291
- ultrasound. *See* obstetric ultrasound
- umbilical cord complications
 - antepartum funic presentation, 45
 - entanglements, nuchal cords, 42–43
 - scope of problem, 42
 - umbilical cord prolapse, 43–44
 - umbilical cord prolapse, documentation, 45
 - umbilical cord prolapse, management protocol, 45
 - velamentous cord insertion, vasa previa, 45–47
- umbilical pain, 292
- upper extremity pain, 291
- urinary tract infections, 433
- uterine contraction monitoring devices, 116–17
- vaccine-preventable disease, 440
- vacuum deliveries, 59
 - application of vacuum, 60–61
 - choice of instruments, 60
 - delivery, 61
- vaginal birth after cesarean section. *See* cesarean section, vaginal birth after
- vaginal deliveries
 - operative, 50
- varicella zoster (Chickenpox), 435–36
- vasa previa, 45–46
 - antepartum diagnosis management recommendations, 249
 - antepartum screening, 249
 - complications, 34–35
 - definition, 248
 - management, 35
 - outcomes, 249
 - risk factors, 248–49
- velamentous cord insertion, 32
 - complications, 33
 - prenatal management, 33–34
- Vesalius, 499
- viral hepatitis, 380
- viral pneumonias
 - chickenpox, 334–35
 - influenza, 334
 - measles, 334
 - Middle East respiratory syndrome, 334
 - pulmonary tuberculosis (PTB), TB screening, 335
- Vitamin D deficiency, 391
- West Nile Virus (WNV), 437
- Witkowski, 498
- Zika virus, 437
- zygosity/chorionicity/epidemiology, 204–05